Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Malarikova D, et al. Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2. Exp Hematol Oncol. 2024. PMID: 38528594 Free PMC article.
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Jakša R, Karolová J, Svatoň M, Kazantsev D, Grajciarová M, Pokorná E, Tonar Z, Klánová M, Winkowska L, Maláriková D, Vočková P, Forsterová K, Renešová N, Dolníková A, Nožičková K, Dundr P, Froňková E, Trněný M, Klener P. Jakša R, et al. Among authors: malarikova d. Lab Invest. 2022 Sep;102(9):957-965. doi: 10.1038/s41374-022-00784-w. Epub 2022 Apr 29. Lab Invest. 2022. PMID: 35488033 Free PMC article.
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M. Obr A, et al. Among authors: malarikova d. Br J Haematol. 2020 Dec;191(5):e103-e106. doi: 10.1111/bjh.17063. Epub 2020 Aug 30. Br J Haematol. 2020. PMID: 32862455 Free article. No abstract available.
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, Vockova P, Salek D, Sykorova A, Furst T, Malarikova D, Papajik T, Trneny M, Klener P. Obr A, et al. Among authors: malarikova d. Ann Hematol. 2023 Jan;102(1):107-115. doi: 10.1007/s00277-022-05023-2. Epub 2022 Nov 11. Ann Hematol. 2023. PMID: 36369497 Free PMC article.
Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research.
Skrlova E, Uherkova E, Klimova A, Malarikova D, Svozilkova P, Matous P, Herynek V, Kucera T, Klener P, Heissigerova J. Skrlova E, et al. Among authors: malarikova d. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Feb 26. doi: 10.5507/bp.2024.003. Online ahead of print. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024. PMID: 38410917
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.
Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, Kriegova E, Prihodova E, Pavlistova L, Petrackova A, Zemanova Z, Trneny M, Klener P. Malarikova D, et al. Cancers (Basel). 2020 Jul 31;12(8):2120. doi: 10.3390/cancers12082120. Cancers (Basel). 2020. PMID: 32751805 Free PMC article.